about
The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humansSubscale validation of the neuropsychiatric inventory questionnaire: comparison of Alzheimer's disease neuroimaging initiative and national Alzheimer's coordinating center cohorts.Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer's disease.Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.Development Review of the BACE1 Inhibitor Lanabecestat (AZD3293/LY3314814).The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.QT effect of semagacestat at therapeutic and supratherapeutic doses.Catheter design influences recurrence of catheter-related bloodstream infection in children with cancer.Validation and Clinical Utility of ELISA Methods for Quantification of Amyloid-β of Peptides in Cerebrospinal Fluid Specimens from Alzheimer’s Disease Studies.Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasiaModeling and simulations to confirm a controlled hypoglycemic stress test in healthy subjects is not associated with clinically significant QT prolongationsEfficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical TrialsPharmacokinetics and Pharmacodynamics of LY2599666, a PEG-Linked Antigen Binding Fragment that Targets Soluble Monomer Amyloid-βClinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P-gp SubstrateAssessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With LanabecestatHippocampal Neuroimaging-Informed Clinical Trial Enrichment Tool for Amnestic Mild Cognitive Impairment Using Open Data
P50
Q27697610-71F7D503-8B87-4FBE-A866-81BFB852FD07Q37555160-6D4CAD1C-7694-4BC2-ACDF-390AD1C90D11Q37639155-B820C5D9-43B4-49CA-A042-6EF5B52EBD99Q43571585-AA7CB6A3-C682-4160-95FE-7433F0BD4EA2Q46209265-506DD0E1-0BE4-47D7-A39C-9DCF29CAF8DCQ48147071-30C736FF-65A8-480C-A60B-BAE510BFBDF0Q51350346-55A3DC65-811A-4553-8E9D-7474BBB36FADQ51825161-53F29542-0E61-4D79-8938-30565BE4CC9EQ53471946-7CBB1980-F97A-48C9-8C61-BAD64149D902Q85941507-578A8602-2C2A-441D-BCB4-CBC866F5BD20Q88004025-1BD58D75-6445-4161-A67B-F96BF34EE48EQ91437540-21412284-261B-4339-9355-480F81C6294CQ91449499-03F2C9F0-2A5F-40CE-BD07-9DFF149BB799Q92106818-72844EAA-E857-4D6A-A091-D33A06D66A9CQ92398642-25DB64C8-20F3-4D18-B620-4F3988D35619Q92402270-0EEF4079-72C5-44C3-82C4-8837DFD73DC0
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Brian Willis
@ast
Brian Willis
@en
Brian Willis
@es
Brian Willis
@nl
type
label
Brian Willis
@ast
Brian Willis
@en
Brian Willis
@es
Brian Willis
@nl
prefLabel
Brian Willis
@ast
Brian Willis
@en
Brian Willis
@es
Brian Willis
@nl
P106
P31
P496
0000-0002-1518-8400